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Abstract (247 words)
Introduction
The burden of chronic headache disorders in the U.S. is substantial. Some patients are treatmentrefractory. Ketamine, an N-methyl-D-aspartate antagonist, provides potent analgesia in
subanesthetic doses in chronic pain and limited data suggest it may alleviate headache in some
patients.
Methods
We performed a retrospective study of 61 patients admitted over 3 years for 5 days of
intravenous therapy that included continuous ketamine to determine responder rate and patient
and ketamine infusion characteristics. Pain ratings at two follow-up visits were recorded. An
immediate responder was a patient with ≥ 2-point decrease in numerical rating scale (0-10 NRS)
from starting to final pain in the hospital. Sustained response at office visits 1 and 2 was
determined based on maintaining the 2-point improvement at those visits. Patients were assessed
daily for pain and adverse events (AEs).
Results
Forty-eight out of the 61 patients (77%) were immediate responders. There were no differences
regarding demographics, opioid use, or fibromyalgia between immediate responders and nonresponders. Maximum improvement occurred 4.56 days (mean) into treatment. Sustained
response occurred in 40% of patients at visit 1 (mean 38.1 days) and 39% of patients at visit 2
(mean 101.3 days). The mean maximum ketamine rate was 65.2 ± 2.8 mg/h; 0.76 mg/kg/h).

3

Ketamine rates did not differ between groups. AEs occurred equally in responders and nonresponders and were mild.
Discussion
Ketamine was associated with short-term analgesia in many refractory headache patients with
tolerable AEs. A prospective study is warranted to confirm this and elucidate responder
characteristics.
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1

Introduction

2

Ketamine, a phencyclidine derivative, is a dissociative anesthetic that provides potent

3

analgesia at subanesthetic doses. It is an N-methyl-D-aspartate (NMDA)-receptor antagonist,

4

which is thought to be the primary mechanism responsible for its analgesic properties. In

5

addition, ketamine acts on opioid, non-NMDA glutamatergic, and muscarinic cholinergic

6

receptors, facilitates GABA signaling, and has local anesthetic properties.1 Subanesthetic

7

ketamine may also be effective for short-term relief of chronic migraine and other refractory

8

headache disorders,2; 3 which affect up to 2% of the population of the United States, inflicting a

9

major clinical and financial burden on patients and the healthcare system.4 The mechanism by

10

which ketamine is effective in treating headache pain is not entirely clear. However,

11

memantine,5; 6 magnesium,7 and amantadine,8 all NMDA-receptor antagonists, may be effective

12

for headache and migraine prophylaxis, which supports the involvement of the NMDA receptor.

13

NMDA-receptor antagonism may decrease chronic pain by inhibiting glutamate-induced

14

neurotoxicity, decreasing central sensitization and specifically in migraines by inhibiting cortical

15

spreading depression (CSD).9 Our clinical experience suggests that there are many patients who

16

experience substantial relief and a smaller group of others who do not benefit from this therapy.

17

We therefore performed a retrospective analysis of patients admitted to our hospital for treatment

18

of refractory headaches over a 3-year period to determine responder rate and patient and

19

ketamine infusion characteristics.

20
21
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2

Methods
After approval by the institutional review board (Thomas Jefferson University, January

3

16, 2014, Control #14D.552), we conducted a retrospective chart review of 61 consecutive

4

patients from January 2014 through December 2016 admitted to Thomas Jefferson University

5

Hospital for intravenous treatment of refractory headache with ketamine infusion. All patients

6

with data available were included. Patients who had previously received ketamine for refractory

7

headache were excluded. Patients were admitted to the neurology service in conjunction with the

8

Jefferson Headache Center for aggressive intravenous (IV) therapy and the acute pain

9

management service (APMS) was consulted for management of intravenous ketamine for each

10

patient. The APMS consists of a physician-led, nurse-driven team that provides coverage 24

11

hours per day, 7 days per week with weekend time being covered by residents. APMS nurses are

12

permitted to adjust ketamine infusion rates within the context of a protocol but they do not give

13

bolus doses (Appendix A). Admission and scheduling was based on bed availability and patients

14

were not necessarily experiencing migraine exacerbations on admission. The electronic medical

15

records, daily APMS notes, and the pre- and post-admission clinic notes from the Jefferson

16

Headache Center were retrieved and the following data were recorded: name; medical record

17

number; demographics; home medications; diagnosis, based on International Classification of

18

Headache Disorders (ICHD-3) criteria;10 pain level on admission, daily pain level during and at

19

the end of hospitalization; ketamine infusion rates and changes during admission; the presence of

20

adverse events (AEs); and medications given to manage AEs. Pain levels from the first two

21

office visits after discharge were recorded.

22

Ketamine infusions were typically started at 10 mg/h for most patients with a few

23

exceptions and titrated up in increments of 5 mg/h every 3-4 h to a soft upper limit of 1 mg/kg/h
6

1

of body weight. AEs, including hallucinations, delirium, blurry vision, nightmares, nausea, and

2

hypertension, were routinely assessed. These AEs were the primary limiting factor in the rate and

3

degree of titration. Admissions were planned to be 5 days unless a patient could not tolerate the

4

full course of treatment or other factors dictated a longer admission. A clonidine patch was used

5

for management of psychomimetic and sympathomimetic adverse effects. A benzodiazepine was

6

also available as needed for treatment of AEs. Other medications routinely ordered by the

7

headache service included, but were not limited to, prochlorperazine, metoclopramide,

8

methylprednisolone, and ketorolac. In general, home analgesics were continued. Daily opioids

9

were being used for management of other comorbid refractory chronic pain conditions, not for

10

the management of refractory headache. In general, patients are routinely counseled by the

11

outpatient headache providers on the risk of opioid use, including MOH. Opioids were being

12

prescribed by non-headache providers. Patients are encouraged to minimize the daily dose of

13

opioids and attempts are made to coordinate alternative management of chronic non-headache

14

pain disorders with other providers.

15

We pre-defined an “immediate responder” as a patient who experienced a decrease in

16

pain rating of 2 points on a 0 to 10 numerical rating scale (NRS) from beginning pain to end

17

pain, consistent with previous investigations.2; 11 A “sustained responder” was defined as an

18

immediate responder who maintained at least a 2-point decrease at the first two post-discharge

19

office visits in the Jefferson Headache Center, each of which was analyzed independently. These

20

two visits are intended to occur at 30 and 90 days after discharge but due to scheduling reasons

21

can vary by several weeks.

22

Continuous parametric data were analyzed using the Student’s t-test for independent

23

groups and the Chi Square test or Fisher’s exact test, as appropriate, for categorical data. All
7

1

statistical analyses were performed using Systat, v.13 (Systat Software Inc., San Jose, CA) with

2

p < 0.05 set for statistical significance. Data are reported as mean ± standard error of the mean

3

(SEM) unless otherwise stated. For office visits 1 and 2, percentages of patients with sustained

4

response were based on patients with available data. Missing patients were not included in those

5

analyses.

6

8

1

Results

2

Headache Pain Outcomes

3

A total of 61 unique patients were identified and included in the study. Demographics are

4

shown in Table 1. It is notable that 13 patients (27%) of the immediate responders and 5 patients

5

(39%) of the non-responders used daily opioids and met the criteria for medication overuse

6

headache (MOH).12 There was no difference between groups regarding MOH (p = 0.499).

7

Additional medications administered during admission included dihydroergotamine, non-

8

steroidal anti-inflammatory drugs, neuroleptics, and anti-convulsants (Table 4). Fifty-nine out of

9

the 61 patients had a diagnosis of refractory migraine on admission and 2 patients had cluster

10

headache. The mean length of infusion was 5.1 ± 0.1 days. The mean pain rating on admission

11

was 7.5 ± 0.2 out of 10 (NRS); this decreased to 3.4 ± 0.3 at the end of ketamine therapy (p <

12

0.001).

13

Using the pre-determined definition of immediate responder as a patient with a decrease

14

in pain rating of 2 out of 10 or greater, 48 of 61 patients (77%) were classified as immediate

15

responders. There were no differences between immediate responders and non-responders with

16

regard to age, sex, history of opioid use, history of fibromyalgia, and presence of AEs (Tables 1

17

and 3). The mean NRS initial pain rating for immediate responders was 7.8 ± 0.23 and 6.8 ± 0.64

18

for non-responders. At the end of treatment, the mean pain rating for immediate responders was

19

2.63 ± 0.28 compared to 6.62 ± 0.68 for non-responders (p < 0.01; Figure 1). The mean time to

20

lowest pain rating was 4.56 days into the admission for immediate responders.

21

At the first office visit, which occurred 38.1 ± 4.7 days after hospital discharge, 52 of the

22

original 61 patients had follow-up data available for analysis. Of the 52 patients, 21 (40%) had a

23

sustained decrease in pain of 2 points and were classified as sustained responders. Thirty patients
9

1

(58%) no longer had sustained response and 1 patient was not an immediate responder but did

2

improve at 1 month compared to the end of hospitalization. Sustained responders did not differ

3

significantly from non-responders with regards to age (p = 0.437) or gender (p = 0.150). At the

4

second office visit, which occurred 101.3 ± 8.8 days after hospital discharge, 49 of the original

5

61 patients had follow-up data available for analysis. Of these, 19 (39%) were classified as

6

sustained responders (Figure 2), while 30 (61%) were not sustained responders at the second

7

office visit. There were no differences between sustained responders and non-responders at this

8

second office visit according to age (p = 0.188) or gender (p = 0.979).

9
10
11

Ketamine Infusion Characteristics
The mean starting ketamine infusion rate for all patients was 11.0 ± 0.6 mg/h (Table 2;

12

Figure 3). The mean weight was 85.4 ± 2.7 kg. The mean maximum ketamine infusion rate was

13

65.2 ± 2.8 mg/h, which is 0.76 mg/kg/h. At the time of the lowest pain rating, the mean ketamine

14

infusion rate was 54.5 ± 3.5 mg/h. There was no difference in mean ketamine infusion rate in

15

immediate responders compared to non-responders over the entire course of treatment (43.7 ±

16

4.2 vs. 44.1 ± 1.9 mg/h; p = 0.933). There was also no difference in the mean maximum

17

ketamine infusion rate between immediate responders and non-responders (64.8 ± 3.0 vs. 66.8 ±

18

7.2 mg/h; p = 0.794).

19
20

Adverse Events

21

Patients were asked daily about the presence of AEs, including central nervous system

22

events (hallucinations, vivid dreams, blurry vision) and nausea and/or vomiting. Sedation was

23

recorded based on nursing or physician observations. Results were recorded as “present” or

24

“absent” and no severity was recorded. Results are shown in Table 3 in decreasing order of
10

1

frequency. All AEs were considered mild and improved following a decrease in ketamine

2

infusion rate, with the exception of one patient, a 52-year-old female who experienced nausea,

3

blurry vision, and sedation on day 2 of treatment and elected to stop ketamine.

11

1
2

Discussion
Our retrospective study of inpatient ketamine infusion shows that over three quarters of

3

patients with refractory headache were immediate responders and about half maintained the

4

improvement up to 3 months after the infusion. Although it cannot be proven that ketamine was

5

solely responsible for the pain relief due to the retrospective nature of the study, it is encouraging

6

and suggests the need for larger, prospective studies in this challenging patient population. The

7

U.S. burden of chronic migraine, which comprised 97% of the diagnoses in our cohort, is

8

substantial, with a prevalence of about 1% of the population.13 The subset of this group carrying

9

a refractory migraine diagnosis is about 5%13 and these patients have substantial disability and

10
11

poor overall quality of life.
Our results mirror and expand upon other retrospective studies with positive results using

12

ketamine for immediate relief of refractory headache.2; 3 One prospective, randomized, double-

13

blinded study reported that subcutaneous ketamine improved acute and subacute pain associated

14

with migraine headaches in 17 patients, although the dosing strategy was unusual.14

15

Our patients achieved maximum pain relief after more than 4 days into their admission.

16

This suggests that satisfactory pain relief may not be achieved after 1 day of treatment and,

17

importantly, not achieving the desired effect during the first few days does not mean further

18

improvement will not occur. Although the mean ketamine infusion rate increased from day 1 to

19

day 4, by day 3 the mean ketamine rate was over 80% of the eventual maximum rate, yet patients

20

continued to experience additional improvement in headache pain. Non-responders experienced

21

mild improvement by day 2 but no further reduction in headache intensity beyond that. Taken

22

together, this suggests clinicians should be patient and wait at least 4 or 5 days before

12

1

determining that someone did not respond to ketamine. For most patients, this requires a full 5-

2

day treatment course.

3

What patient characteristics might help predict response? None of the demographic

4

factors or the presence of fibromyalgia or current opioid use was significantly associated with

5

response to ketamine. Fibromyalgia and opioid use are potential confounders given the evidence

6

supporting ketamine for short-term relief in fibromyalgia15 as well as studies showing opioid-

7

tolerant patients especially benefit from ketamine.16; 17 Well-designed prospective studies are

8

needed to better elucidate these characteristics as retrospective data have limitations. Other

9

factors might help predict response to ketamine, such as individual metabolism of the drug.18

10

Metabolites of ketamine, including hydroxyketamine, dehydronorketamine, and other

11

hydroxynorketamine molecules, may play a role in the treatment of depression19 and they could

12

also be important in chronic pain conditions such as complex regional pain syndrome (CRPS).18

13

There is a subset of migraine and CRPS patients who have favorable response to ketamine while

14

others have minimal relief. Tailoring treatment based on likelihood of response would be useful

15

to patients and clinicians. This is an area worthy of future study.

16

The widespread use of ketamine for refractory headache disorders remains challenging.

17

The psychomimetic AEs, including hallucinations, vivid dreams, and other central nervous

18

system excitation, associated with ketamine deter many from using it. In addition, since it is

19

approved as an anesthetic, it requires monitoring that varies by the state and hospital. The

20

incidence of such undesirable AEs in one review of postoperative patients was about 7%.20 In a

21

mixed medical/surgical population receiving subanesthetic ketamine infusions an incidence of

22

16% was reported, while in a refractory headache population this was as high as 20% of patients

23

with a mean ketamine rate of 0.53 mg/kg/h.2 Our incidence of hallucinations (28%) was higher
13

1

than these reported results and this may have been a result of our fairly aggressive titration of

2

ketamine with a mean maximum rate of 65 mg/h (0.76 mg/kg/h). Despite our higher rates, only

3

one patient discontinued infusion due to intolerance of AEs. This is encouraging as higher doses

4

appear to be well tolerated by most patients.

5

In addition to the inherent limitations of any retrospective study, this study has several

6

additional limitations. First, patients were not necessarily admitted for treatment during an acute

7

exacerbation of migraine, thus initial pain ratings may not have reflected the overall state of the

8

headache disorder. Second, our ketamine protocol does not mandate a specific starting dose and

9

allows for some clinical judgment in rate increases and decreases. There is variation in the

10

titration strategy among our individual APMS physicians. Third, because 97% of patients in the

11

study had a migraine diagnosis it is not clear how generalizable these results would be to patients

12

with other headache diagnoses. Last, we were unable to retrospectively determine with certainty

13

if patients had any changes in treatment or other interventions after hospital discharge that could

14

have affected level of pain at subsequent office visits. This limitation likely did not play a major

15

role in the results as all patients in the study had refractory headaches and were unlikely to have

16

responded to other minor interventions during that time.

17

In conclusion, subanesthetic ketamine infusion was associated with improved acute pain

18

in a group of patients with refractory headaches, many of whom continued to experience

19

decreased pain 3 months after treatment. Ketamine is a promising potential therapy for thousands

20

of refractory patients who have not found relief elsewhere. Ketamine infusion is well tolerated

21

within the context of our protocol. Prospective studies should focus on responder characteristics

22

and optimal dosing strategies that minimize AEs while providing optimal headache relief.

14

Table 1. Demographic data
Variable

All Patients
N=61
44/17
42.4 (20 – 65)
85.4 (2.7)
59 (97)
2 (3)

Male/Female (N)
Age (years), mean (range)
Weight (kg), mean (SEM)
Migraine, N (%)
Cluster Headache, N (%)

Variable
Male Patients, N (%)
Age (years), mean (SEM)
Daily Opioid Use, N (%)
Fibromyalgia, N (%)

Immediate
Responders
N=48
13 (27)
43.2 (1.7)
32 (67)
9 (19)

Non-Responders
N=13

P value

6 (46)
39.2 (3.4)
6 (46)
2 (15)

0.191
0.355
0.570
0.781

15

Table 2. Ketamine infusion data

Mean Starting Rate (mg/h)

Immediate
Responders
N=48
11.0 (0.7)

Mean Infusion Rate (mg/h)

43.7 (4.2)

44.1 (1.9)

0.933

Maximum Infusion Rate (mg/h)

64.8 (3.0)

66.8 (7.2)

0.794

Non-Responders
N=13

P value

10.8 (0.8)

0.853

Data are presented as mean (SEM)

16

Table 3. Adverse events from ketamine infusions
Adverse Events

Immediate
Responders
N=48
36 (75)

Non-Responders
N=13

P value

7 (54)

0.141

Sedation

23 (48)

8 (62)

0.319

Nausea/Vomiting

19 (40)

4 (31)

0.564

Blurry Vision

17 (35)

6 (46)

0.482

Hallucinations

13 (27)

4 (31)

0.794

Vivid Dreams

5 (10)

3 (23)

0.234

Nystagmus

Data are presented as N (%)

17

Table 4. Additional medications used for patients with refractory headache

IV/Nasal DHE

Immediate
Responders
N=48
14 (29.1%)

IV NSAIDs

22 (45.8%)

6 (4.6%)

PO NSAIDs

8 (16.6%)

1 (7.7%)

IV Neuroleptics

10 (20.8%)

1 (7.7%)

PO Neuroleptics

24 (50%)

8 (61.5%)

IV Anticonvulsants

2 (4.2%)

0

PO Anticonvulsants

21 (43.8%)

5 (38.4%)

Non-Responders
N=13
1 (7.7%)

DHE = dihydroergotamine; IV = intravenous; NSAID = non-steroidal anti-inflammatory drug;
PO = by mouth

18

Figure Legends
Figure 1. Pain experienced during admission by patients with refractory headaches being treated
with continuous 5-day ketamine infusions (SEM = standard error of the mean)
Figure 2. Percentage of patients characterized as responders acutely and at office visits 1 and 2

Figure 3. Ketamine infusion rates at various points of treatment (SEM = standard error of the
mean)

19
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